Business Wire

CQN-ALTER-DOMUS

10.5.2022 11:48:12 CEST | Business Wire | Press release

Share
CORRECTING and REPLACING Alter Domus Launches Industry-Leading ESG Reporting Solution for Alternative Investment Managers

Third bullet in the body of the release should read: "Tailored benchmarking against peers and operational support" (instead of "Tailored benchmarking against peers and operational advisory")

The updated release reads:

ALTER DOMUS LAUNCHES INDUSTRY-LEADING ESG REPORTING SOLUTION FOR ALTERNATIVE INVESTMENT MANAGERS

Fund administrator unveils comprehensive and innovative ESG solution that provides regulatory and signatory support for clients

Alter Domus, a leading provider of integrated solutions for the alternative investment industry, today announced it has launched an industry-leading Environmental, Social & Governance (ESG) reporting solution.

Despite a lack of standardized ESG models available, demand for ESG data is booming.1 This trend has placed additional strain on alternatives managers who are increasingly fielding ESG data requests from investors, regulators, and non-governmental organizations without a clear directive on how to report or share this data.

Designed specifically for alternative assets, Alter Domus’ ESG Reporting Solution is a cloud-based digital platform that provides comprehensive, tailored reports for clients that collect, store, and disseminate corporate ESG data. Alter Domus’ ESG Reporting Solution will be accessible through an online, user-friendly portal that ensures secure access and management of client data.

Other features of Alter Domus’ ESG Reporting Solution include:

  • Scoring and ratings for a fund or portfolio based on internationally recognized standards
  • Data analysis that can be shared with stakeholders, including regulators for disclosure, compliance, and other reporting purposes
  • Tailored benchmarking against peers and operational support

“Today’s announcement underscores Alter Domus’ commitment to developing and offering the most innovative products that our clients need at a global scale,” said Alex Traub, Chief Commercial Officer. “ESG has become an important part of investment philosophies for investors at every level, and we expect this trend to continue even further as ESG becomes more standardized and mainstream with alternative managers.”

“We have heard from our clients globally about the need for a standardized ESG reporting framework and solution that can be integrated across all of their operations seamlessly,” said Antonis Anastasiou, Managing Director of the Alter Domus Management Company S.A. “We worked to develop this solution that helps our clients not only navigate the complexities of ESG regulation, but to also provide their own investors with the types of reporting they need.”

For its part, and as a growing organization with an increasingly global footprint, Alter Domus ensures that ESG factors are considered as standard practice in all strategic business planning and decision making. Further, Alter Domus is a signatory of the United Nations-supported Principles for Responsible Investment, and aligned with The World Economic Forum (WEF) Measuring Stakeholder Capitalism; Towards Common Metrics and Consistent Reporting of Sustainable Value Creation framework.

Over the last 12 months, Alter Domus has seen increasing demand for alternative investments, particularly in Europe and the United States. Having doubled their assets under administration in that time, Alter Domus is at the forefront of delivering timely, technology-driven solutions to alternative asset managers, lenders, and asset owners globally.

About Alter Domus

Alter Domus is a leading provider of integrated solutions, serving private equity, real assets and debt capital markets sectors with more than 3,600 employees across 36 offices globally. Solely dedicated to alternatives, Alter Domus offers fund administration, corporate services, depositary services, capital administration, transfer pricing, domiciliation, management company services, loan administration, agency services, trade settlement and CLO manager services. Find out more at www.alterDomus.com .

____________________
1 Opimas Research: http://www.opimas.com/research/547/detail/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye